MX338210B - Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin -4-il-fenil)-n4-[2- (propan-2-sulfonil)-fenil]-pirimidin-2,4-diami na. - Google Patents

Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin -4-il-fenil)-n4-[2- (propan-2-sulfonil)-fenil]-pirimidin-2,4-diami na.

Info

Publication number
MX338210B
MX338210B MX2013006952A MX2013006952A MX338210B MX 338210 B MX338210 B MX 338210B MX 2013006952 A MX2013006952 A MX 2013006952A MX 2013006952 A MX2013006952 A MX 2013006952A MX 338210 B MX338210 B MX 338210B
Authority
MX
Mexico
Prior art keywords
phenyl
crystalline forms
isopropoxy
diamine
chloro
Prior art date
Application number
MX2013006952A
Other languages
English (en)
Spanish (es)
Other versions
MX2013006952A (es
Inventor
Lili Feng
Piotr H Karpinski
Liladhar Murlidhar Waykole
Baoqing Gong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX338210(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2013006952A publication Critical patent/MX2013006952A/es
Publication of MX338210B publication Critical patent/MX338210B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hydrogenated Pyridines (AREA)
MX2013006952A 2010-12-17 2011-12-15 Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin -4-il-fenil)-n4-[2- (propan-2-sulfonil)-fenil]-pirimidin-2,4-diami na. MX338210B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424194P 2010-12-17 2010-12-17
PCT/US2011/065030 WO2012082972A1 (en) 2010-12-17 2011-12-15 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

Publications (2)

Publication Number Publication Date
MX2013006952A MX2013006952A (es) 2013-07-15
MX338210B true MX338210B (es) 2016-04-07

Family

ID=45464892

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006952A MX338210B (es) 2010-12-17 2011-12-15 Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin -4-il-fenil)-n4-[2- (propan-2-sulfonil)-fenil]-pirimidin-2,4-diami na.

Country Status (36)

Country Link
US (2) US9309229B2 (cg-RX-API-DMAC7.html)
EP (3) EP3121171B1 (cg-RX-API-DMAC7.html)
JP (1) JP5916752B2 (cg-RX-API-DMAC7.html)
KR (4) KR20180032680A (cg-RX-API-DMAC7.html)
CN (7) CN106831716A (cg-RX-API-DMAC7.html)
AR (2) AR084309A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011343775B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013015000A2 (cg-RX-API-DMAC7.html)
CA (1) CA2821102C (cg-RX-API-DMAC7.html)
CL (1) CL2013001723A1 (cg-RX-API-DMAC7.html)
CO (1) CO6801792A2 (cg-RX-API-DMAC7.html)
CY (2) CY1119474T1 (cg-RX-API-DMAC7.html)
DK (2) DK3121171T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012770A (cg-RX-API-DMAC7.html)
ES (3) ES2696526T3 (cg-RX-API-DMAC7.html)
GT (1) GT201300153A (cg-RX-API-DMAC7.html)
HR (2) HRP20171477T1 (cg-RX-API-DMAC7.html)
HU (1) HUE041845T2 (cg-RX-API-DMAC7.html)
IL (1) IL226474A (cg-RX-API-DMAC7.html)
LT (2) LT3121171T (cg-RX-API-DMAC7.html)
MA (1) MA34771B1 (cg-RX-API-DMAC7.html)
MX (1) MX338210B (cg-RX-API-DMAC7.html)
MY (2) MY177742A (cg-RX-API-DMAC7.html)
NZ (1) NZ610713A (cg-RX-API-DMAC7.html)
PE (1) PE20140698A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013501254A1 (cg-RX-API-DMAC7.html)
PL (2) PL3121171T3 (cg-RX-API-DMAC7.html)
PT (2) PT2651918T (cg-RX-API-DMAC7.html)
RS (1) RS57771B1 (cg-RX-API-DMAC7.html)
RU (2) RU2599785C3 (cg-RX-API-DMAC7.html)
SG (2) SG190856A1 (cg-RX-API-DMAC7.html)
SI (2) SI2651918T1 (cg-RX-API-DMAC7.html)
TN (1) TN2013000216A1 (cg-RX-API-DMAC7.html)
TW (2) TWI576344B (cg-RX-API-DMAC7.html)
WO (1) WO2012082972A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201303599B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3121171B1 (en) 2010-12-17 2018-08-15 Novartis Ag Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
CN104854101B (zh) 2012-11-06 2018-05-01 上海复尚慧创医药研究有限公司 Alk激酶抑制剂
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
CN105294649B (zh) * 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
CN105294650A (zh) * 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
CN111888368B (zh) 2014-10-21 2024-02-02 武田药品工业株式会社 5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的晶形
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
CN105601614A (zh) * 2014-11-21 2016-05-25 奥浦顿（上海）医药科技有限公司 一种色瑞替尼晶型及其制备方法
WO2016082795A1 (zh) * 2014-11-28 2016-06-02 苏州晶云药物科技有限公司 色瑞替尼的晶型i及其制备方法
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016108123A2 (en) * 2014-12-17 2016-07-07 Dr. Reddy’S Laboratories Limited Pure amorphous and amorphous solid dispersion of ceritinib
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2016098042A1 (en) * 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
EP3328848A1 (en) 2015-07-28 2018-06-06 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) * 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
WO2017152858A1 (zh) * 2016-03-11 2017-09-14 苏州晶云药物科技有限公司 色瑞替尼的晶型及其制备方法
WO2017158619A1 (en) 2016-03-15 2017-09-21 Natco Pharma Limited A modified process for the preparation of ceritinib and amorphous form of ceritinib
JP2019196359A (ja) * 2019-06-17 2019-11-14 ノバルティス アーゲー ピリミジン誘導体およびそれらの中間体を調製する化学的方法
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
EP4092021B1 (en) 2020-01-17 2025-11-12 Xuanzhu Biopharmaceutical Co., Ltd. Crystal form of polycyclic anaplastic lymphoma kinase inhibitor
KR20230008047A (ko) * 2020-03-30 2023-01-13 장슈 야홍 메디텍 코퍼레이션 리미티드 니트록솔린 전구약물의 결정 형태, 이를 함유하는 약학 조성물, 및 이의 제조 방법 및 이의 용도
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
SI2287156T1 (sl) * 2003-08-15 2013-09-30 Novartis Ag 2,4-di(fenilamino)-pirimidini, uporabni pri zdravljenju neoplastičnih bolezni, vnetnih motenj in motenj imunskega sistema
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP2311807B1 (en) 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0815979A2 (pt) * 2007-08-28 2017-06-13 Irm Llc compostos e composições com inibidores de quinase, bem como uso dos mesmos
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
KR101238585B1 (ko) 2008-04-07 2013-02-28 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
PL2300013T5 (pl) * 2008-05-21 2025-04-28 Takeda Pharmaceutical Company Limited Pochodne fosforu jako inhibitor kinazy
US20120142667A1 (en) * 2009-06-10 2012-06-07 Nigel Ramsden Pyrimidine derivatives as zap-70 inhibitors
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
KR102000301B1 (ko) 2010-12-17 2019-07-15 리아타 파마슈티컬즈, 아이엔씨. 산화방지성 염증 조절제로서의 피라졸릴 및 피리미디닐 트리사이클릭 엔온
JP2014501246A (ja) 2010-12-17 2014-01-20 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ性アゾ環式アミド
EP3121171B1 (en) 2010-12-17 2018-08-15 Novartis Ag Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
CN105294650A (zh) 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
DE112015005255B4 (de) 2014-11-21 2023-10-26 Joyson Safety Systems Acquisition Llc Airbagmodul
CN105622577A (zh) 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
KR20170088984A (ko) 2014-12-04 2017-08-02 브리스톨-마이어스 스큅 컴퍼니 암 (골수종)을 치료하기 위한 항-cs1 항체와 항-pd1 항체의 조합
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
EP3328848A1 (en) 2015-07-28 2018-06-06 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用

Also Published As

Publication number Publication date
CN106831716A (zh) 2017-06-13
IL226474A (en) 2016-03-31
WO2012082972A1 (en) 2012-06-21
TN2013000216A1 (en) 2014-11-10
ECSP13012770A (es) 2013-10-31
RU2599785C3 (ru) 2019-04-24
US20160175305A1 (en) 2016-06-23
HRP20171477T1 (hr) 2017-11-17
CA2821102C (en) 2019-06-11
CL2013001723A1 (es) 2013-12-27
PH12013501254A1 (en) 2016-07-29
KR20190022903A (ko) 2019-03-06
SG10201510082XA (en) 2016-01-28
AU2011343775A1 (en) 2013-07-18
AU2011343775B2 (en) 2015-12-03
CO6801792A2 (es) 2013-11-29
HUE041845T2 (hu) 2019-05-28
CN106008462A (zh) 2016-10-12
RU2599785C2 (ru) 2016-10-20
MX2013006952A (es) 2013-07-15
EP3453708B8 (en) 2022-03-16
LT3121171T (lt) 2018-11-12
PL3121171T3 (pl) 2019-01-31
CA2821102A1 (en) 2012-06-21
KR20200039021A (ko) 2020-04-14
US20130274279A1 (en) 2013-10-17
SG190856A1 (en) 2013-07-31
CN107056751A (zh) 2017-08-18
ES2696526T3 (es) 2019-01-16
SI3121171T1 (sl) 2018-11-30
TW201307299A (zh) 2013-02-16
RU2746159C2 (ru) 2021-04-08
IL226474A0 (en) 2013-07-31
RU2016136823A3 (cg-RX-API-DMAC7.html) 2020-02-06
TWI576344B (zh) 2017-04-01
US9309229B2 (en) 2016-04-12
ES2905973T3 (es) 2022-04-12
CN103282359A (zh) 2013-09-04
CY1119474T1 (el) 2018-04-04
KR20130130022A (ko) 2013-11-29
EP3453708A1 (en) 2019-03-13
MY164810A (en) 2018-01-30
RU2016136823A (ru) 2018-12-11
TW201629021A (zh) 2016-08-16
TWI576343B (zh) 2017-04-01
ES2643016T3 (es) 2017-11-21
AR122395A2 (es) 2022-09-07
PT2651918T (pt) 2017-10-17
EP2651918A1 (en) 2013-10-23
JP2013545812A (ja) 2013-12-26
EP3121171A1 (en) 2017-01-25
EP3453708B1 (en) 2021-10-27
JP5916752B2 (ja) 2016-05-11
DK3121171T3 (en) 2018-12-10
PE20140698A1 (es) 2014-06-11
RU2013132947A (ru) 2015-01-27
ZA201303599B (en) 2014-02-26
HRP20181737T1 (hr) 2018-12-28
CN112125884A (zh) 2020-12-25
DK2651918T3 (en) 2017-10-23
PL2651918T3 (pl) 2017-12-29
RS57771B1 (sr) 2018-12-31
CN114989139A (zh) 2022-09-02
SI2651918T1 (sl) 2017-10-30
PT3121171T (pt) 2018-11-27
LT2651918T (lt) 2017-10-10
CY1121017T1 (el) 2019-12-11
NZ610713A (en) 2014-10-31
MA34771B1 (fr) 2013-12-03
EP2651918B1 (en) 2017-07-12
MY177742A (en) 2020-09-23
KR20180032680A (ko) 2018-03-30
EP3121171B1 (en) 2018-08-15
CN104262324A (zh) 2015-01-07
KR102325775B1 (ko) 2021-11-12
GT201300153A (es) 2014-06-09
AR084309A1 (es) 2013-05-08
BR112013015000A2 (pt) 2016-08-09

Similar Documents

Publication Publication Date Title
TN2013000216A1 (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
PL3290414T3 (pl) Sposób otrzymywania n-[5-(3,5-difluorobenzylo)-1h-indazol-3-ilo]-4-(4-metylopiperazyn-1-ylo)-2-(tetrahydropiran-4-yloamino)benzamidu
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
EA201391318A1 (ru) Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
EA201101194A1 (ru) Применение розувастатин лактолов в качестве лекарственных препаратов
UA86731C2 (ru) Делимая галеновая форма модифицированного высвобождения активного ингредиента
MY180581A (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
AR088936A1 (es) Formulaciones farmaceuticas
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
MX353334B (es) N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pi rimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina.
EA201001870A1 (ru) Новые кристаллические формы рабепразола натрия
EP3031465A4 (en) Pharmaceutical composition for promoting bone tissue formation, containing stauntonia hexaphylla leaf extract as active ingredient
TN2016000207A1 (en) Pharmaceutical dosage forms.
EA200970816A1 (ru) Новая лекарственная форма
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase
MX2012010491A (es) Compuestos arilvinilazacicloalcano para la constipacion.
UY34497A (es) Formas cristalinas de [(S)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida de ácido 2-(2-metilamino-pirimidin-4-il)-1H-indol-5-carboxílico.
EP2564844A4 (en) COMPOSITION FOR THE TREATMENT OF BONE DISORDERS WITH A GLYCEOLINE AS AN ACTIVE SUBSTANCE
UA103544C2 (uk) Кристалічна форма і цинкової солі розувастатину
EA201390700A1 (ru) Кристаллические фармацевтически активные ингредиенты
TH145940A (th) รูปผลึกของ 5-คลอโร-n2-(2-ไอโซโพรพอกซี-5-เมธิล-4-ไพเพอริดิน-4-อิล-เฟนิล)-n4-[2-(โพรเพน-2-ซัลโฟนิล)-เฟนิล]-ไพริมิดีน-2,4-ไดเอมีน

Legal Events

Date Code Title Description
FG Grant or registration